EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Phase II study of CIMAvax EGF plus nivolumab in previously treated, immunotherapy-naïve advanced NSCLC

Rachel Frascati, Andrei Gudkov, Mary E. Reid, Kelvin Lee, Jason B. Muhitch, Circe Mesa, Patricia L. Luaces, Orestes Santos-Morales, Ivan A. Bespalov, Hans Minderman, Joseph D. Tario, Victoria Fitzpatrick und 13 weitere

Cancer Immunology, Immunotherapy · 29.10.2026

DOI: 10.1007/s00262-026-04615-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 29.10.2026. Verfasst von Rachel Frascati und 24 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI Cancer Center Support Grant, Roswell Park Alliance Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

CIMAvax-EGF is a novel epidermal growth factor (EGF)-depleting therapy that induces the development of anti-EGF antibodies to clear free serum EGF from circulation. The primary objective of this single-arm phase II trial (NCT02955290) was to evaluate 12-month overall survival (OS) in patients receiving CIMAvax-EGF and Nivolumab for previously treated, immunotherapy-naïve advanced NSCLC.

Methods

Patients received 2.4 mg of CIMAvax-EGF intramuscularly every 2 weeks for four doses (loading phase) then continued monthly maintenance. Nivolumab was given 240 mg intravenously every 2 weeks. OS and progression-free survival (PFS) data were determined using a Kaplan–Meier test with 95% confidence intervals.

Results

Twenty-one pts completed the loading phase (PP). Disease control rate was 47.6% ( n = 10). The PP patients had a 48% 12-month OS and 29% 3-year OS rate. Median OS for PP pts was 11.9 months. Ability to inhibit EGFR phosphorylation using individual patient post-vaccination available sera correlated with survival, with greater inhibition associated with longer median OS (11.3 vs 6.5 months). Median OS, 1-yr and 3-yr OS for EGFR/ALK/KRAS wild-type pts were 31.7 months, 67%, 50%, respectively, and 10.1 months, 29%, 0%, respectively, in KRAS mutated pts.

Discussion

The combination of CIMAvax-EGF and nivolumab demonstrated improved survival compared to historical nivolumab monotherapy cohorts. Patients with EGFR/ALK/KRAS wild-type tumors derived greatest benefit. Sera collected after CIMAvax-EGF loading phase showed inhibition of EGFR phosphorylation, and higher level of inhibition correlated with longer survival. These findings suggest that CIMAvax-EGF is feasible to combine with PD-1 blockade and may have additive activity, particularly in EGFR/ALK/KRAS wild-type NSCLC.

Förderung

  • NCI Cancer Center Support Grant
  • Roswell Park Alliance Foundation

Zitieren

APA

Frascati, R., Gudkov, A., Reid, M. E., Lee, K., Muhitch, J. B., Mesa, C., Luaces, P. L., Santos-Morales, O., Bespalov, I. A., Minderman, H., Tario, J. D., Fitzpatrick, V., Dozier, A., Ford, C., Liu, X., Fountzilas, C., Gandhi, S., Attwood, K., Groman, A., …, & Dy, G. K. (2026). Phase II study of CIMAvax EGF plus nivolumab in previously treated, immunotherapy-naïve advanced NSCLC. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04615-5

Vancouver

Frascati R, Gudkov A, Reid ME, Lee K, Muhitch JB, Mesa C, et al. Phase II study of CIMAvax EGF plus nivolumab in previously treated, immunotherapy-naïve advanced NSCLC. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04615-5

BibTeX
@article{Frascati2026,
  author = {Frascati, Rachel and Gudkov, Andrei and Reid, Mary E. and Lee, Kelvin and Muhitch, Jason B. and Mesa, Circe and Luaces, Patricia L. and Santos-Morales, Orestes and Bespalov, Ivan A. and Minderman, Hans and Tario, Joseph D. and Fitzpatrick, Victoria and Dozier, Askia and Ford, Cayla and Liu, Xiaojun and Fountzilas, Christos and Gandhi, Shipra and Attwood, Kristopher and Groman, Adrienne and Johnson, Candace and Herrera, Zaima Mazorra and Saavedra, Danay and Leon, Kalet and Ramos, Tania Crombet and Dy, Grace K.},
  title = {Phase II study of CIMAvax EGF plus nivolumab in previously treated, immunotherapy-naïve advanced NSCLC},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04615-5}
}
Kostenlos starten →